Access the updated page using the API Locator.   Our Custom Search for Pharma News…

FDA Approval Activities for this Drug… Maxalt (rizatriptan benzoate) Tablets & Maxalt-MLT (orally disintegrating tablet), 5 and 10 mg, Merck NDA 20-864/S8 & 20-865/S9 4/22/02 5/2/02 | Maxalt (rizatriptan benzoate) Tablets & Maxalt-MLT (orally disintegrating tablet), 5 and 10 mg, Merck NDA 20-864 & 20-865 6/29/98 6/30/98 6/30/98 4/8/99 | Maxalt Indication: Migraine | Maxalt (rizatriptan)5 and 10 mg, . Merck & Co., NDA 20-865/S-001 NDA 20-864/S-003 | Rizatriptan Benzoate Orally Disintegrating Tablets, Mylan Pharmaceuticals, Tentative Approval | Rizatriptan Benzoate Tablets, Teva Pharma, Tentative Approval | Rizatriptan Benzoate Tablets, Sandoz Inc., Tentative Approval | Maxalt (rizatriptan benzoate) Tablets, Merck Sharp & Dohme Corp., Labeling Revision | Maxalt-MLT (rizatriptan benzoate) Orally Disintegrating Tablets, Merck Sharp & Dohme Corp., Labeling Revision | Rizatriptan Benzoate Orally Disintegrating Tablets, Sandoz, Inc., Tentative Approval | Rizatriptan Benzoate Tablets, Cipla Ltd., Tentative Approval View updates.                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | VOIP © 2012 Betterchem.com